Revenue
$97.93B
Fiscal year ended 2026-06-28Operating income
Unavailable
Fiscal year ended 2026-06-28Free cash flow
$22.24B
Fiscal year ended 2026-06-28JOHNSON & JOHNSON (JNJ) reported revenue of $97.93B and net income of $21.04B for the fiscal year ended 2026-06-28. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from JOHNSON & JOHNSON’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-28 |
|---|---|
| Revenue | $97.93B |
| Cost of revenue | $31.43B |
| Gross profit | $66.50B |
| Operating income | Unavailable |
| Net income | $21.04B |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $25.20B |
| Income tax expense | $4.16B |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $25.14B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-28 |
|---|---|
| Cash & equivalents | $20.42B |
| Total assets | $201.06B |
| Current assets | $59.77B |
| Total liabilities | $116.09B |
| Current liabilities | $54.90B |
| Total equity incl. NCI | $84.97B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $15.14B |
| Accounts receivable | $19.05B |
| Goodwill | $48.48B |
| Long-term debt | $37.34B |
| Accounts payable | $9.22B |
Cash flow
| Metric | 2026-06-28 |
|---|---|
| Operating cash flow | $27.61B |
| Capital expenditures | $5.36B |
| Investing cash flow | -$7.18B |
| Financing cash flow | -$18.54B |
| Net change in cash | $1.84B |
| Stock-based compensation | $1.41B |
| Common dividends paid | $12.62B |
| Common share repurchases | $8.08B |
| Depreciation & amortization | $7.75B |
Derived
| Metric | 2026-06-28 |
|---|---|
| Free cash flow | $22.24B |
| Gross margin | 67.9% |
| Operating margin | Unavailable |
| FCF margin | 22.7% |
| SBC / revenue | 1.4% |
| Current ratio | 1.09x |
| Revenue YoY growth | 8.1% |
| Net margin | 21.5% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 5.5% |
| Long-term debt / equity | 0.44x |
| Effective tax rate | 16.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JNJ in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-22View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-10-22View SEC filing
10-Q · Filed 2025-07-24View SEC filing
10-Q · Filed 2025-04-23View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.